Indimacis 125 (igovomab)
- Region
- 🇪🇺 EU
- Active substance
- igovomab
- Company
- CIS bio international
- Status
- Withdrawn
- Therapeutic area
- Radionuclide Imaging; Ovarian Neoplasms
- EU approval
- Fri 04 Oct 1996
- Application
- EMEA/H/C/000065
- ATC
- V09IB03
- Official record
- www.ema.europa.eu
Indication
Positive diagnosis of relapsing ovarian adenocarcinoma when serum CA 125 is increased without positive results of ultrasound or computerised tomography scan.
Regulatory milestones
No milestones recorded in the last year.
Follow Indimacis 125
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.